The federal regulator made questionable calls to "accommodate" the manufacturer of the anticoagulant Pradaxa, the Project on Government Oversight says in a new investigation, from setting loose standards for the drug’s company-sponsored clinical trial to a lack of proper warnings to patients about its potential health hazards.
Read Full Article »
